Tech Company Financing Transactions
Immunai Funding Round
Immunai closed a $215 million Series B funding round on 10/30/2021. Investors included Koch Disruptive Technologies, 8VC and Alexandria Venture Investments.
Transaction Overview
Company Name
Announced On
10/30/2021
Transaction Type
Venture Equity
Amount
$215,000,000
Round
Series B
Investors
Proceeds Purpose
This round will be used to bring in more employees and to keep enriching the immunological data set (and back-end infrastructure that can support it) at the company's disposal.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
180 Varick St. 6th Floor
New York, NY 10014
USA
New York, NY 10014
USA
Phone
Undisclosed
Website
Email Address
Overview
Immunai was founded in December 2018. We are a multidisciplinary team of immunologists, genomics technologists, computer scientists, engineers, mathematicians and operators singularly focused on solving an audacious challenge. Backed by some of the leading scientific minds in immunology, oncology, and single cell genomics, we are up for the challenge.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Noam Solomon
Chief Technical Officer
Luis Voloch
Co-Founder
Daniel Littman
Co-Founder
Ansuman Satpathy
VP - Bus. Development
Alex Cogdill
VP - Product Management
Sen Zhang
VP - R & D
Danny Wells
Browse more venture capital transactions:
Prev: 10/30/2021: ShiftMed venture capital transaction
Next: 10/30/2021: UserGems venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs